News
LXRX
2.050
+0.74%
0.015
Beta Bionics, J.B. Hunt Transport And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Benzinga · 4d ago
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Benzinga · 4d ago
Weekly Report: what happened at LXRX last week (0907-0911)?
Weekly Report · 6d ago
Lexicon Pharmaceuticals (LXRX) Receives a Buy from Citi
TipRanks · 09/11 08:25
Weekly Report: what happened at LXRX last week (0831-0904)?
Weekly Report · 09/07 09:31
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
Barchart · 09/01 15:05
Lexicon announces results from post hoc analysis of SOLOIST-WHF trial
TipRanks · 08/31 12:55
Weekly Report: what happened at LXRX last week (0824-0828)?
Weekly Report · 08/31 09:34
Lexicon Earns Third $10 Mln Milestone Payment From Novo For LX9851
NASDAQ · 08/25 02:09
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT)
TipRanks · 08/24 14:50
Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk
Dow Jones · 08/24 13:12
Lexicon earns third $10M milestone payment from Novo Nordisk for LX9851
TipRanks · 08/24 12:45
Lexicon earns third $10M Novo milestone
Seeking Alpha · 08/24 12:42
Weekly Report: what happened at LXRX last week (0817-0821)?
Weekly Report · 08/24 09:34
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
Barchart · 08/24 07:30
Lexicon Pharmaceuticals Earnings Call: Pipeline Drives Story
TipRanks · 08/22 00:20
Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets
Seeking Alpha · 08/19 14:19
Weekly Report: what happened at LXRX last week (0810-0814)?
Weekly Report · 08/17 09:35
Weekly Report: what happened at LXRX last week (0803-0807)?
Weekly Report · 08/10 09:32
Lexicon Pharmaceuticals (LXRX) Receives a Buy from Piper Sandler
TipRanks · 08/07 15:28
More
Webull provides a variety of real-time LXRX stock news. You can receive the latest news about Lexicon Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About LXRX
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.